Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Aligos Therapeutics, Inc. (ALGS) reported a Q3 loss of $3.07 per share, which was larger than the Zacks Consensus Estimate of a $2.15 loss. However, this is an improvement from the $10.25 loss per share a year ago.
November 07, 2024 | 12:30 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aligos Therapeutics reported a Q3 loss of $3.07 per share, missing the Zacks Consensus Estimate of a $2.15 loss. Despite missing estimates, the loss is an improvement from the previous year's $10.25 per share.
The reported loss per share was worse than expected, which is typically negative for stock prices. However, the improvement from the previous year's loss may mitigate some negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100